Cargando…

Treating acute cough: wet versus dry – have we got the paradigm wrong?

It is time to abandon the dry/wet classification of acute cough due to URTI http://ow.ly/Sfc1X

Detalles Bibliográficos
Autores principales:	Morice, Alyn H., Kantar, Ahmad, Dicpinigaitis, Peter V., Birring, Surinder S., McGarvey, Lorcan P., Chung, Kian Fan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2015
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005123/ https://www.ncbi.nlm.nih.gov/pubmed/27730158 http://dx.doi.org/10.1183/23120541.00055-2015

Ejemplares similares

Chronic cough: new insights and future prospects
por: Morice, Alyn, et al.
Publicado: (2021)

Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials
por: McGarvey, Lorcan, et al.
Publicado: (2016)

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
por: Muccino, David R., et al.
Publicado: (2020)

From bench to bedside: The role of cough hypersensitivity in chronic cough
por: Drake, Matthew G., et al.
Publicado: (2023)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough
por: McGarvey, Lorcan, et al.
Publicado: (2022)

Reply to Weinberger
por: Birring, Surinder S., et al.
Publicado: (2023)

Cough hypersensitivity and chronic cough
por: Chung, Kian Fan, et al.
Publicado: (2022)

The Effect of Aclidinium on Symptoms Including Cough in Chronic Obstructive Pulmonary Disease: A Phase 4, Double-Blind, Placebo-controlled, Parallel-Group Study
por: Smith, Jaclyn A., et al.
Publicado: (2019)

Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks
por: Birring, Surinder S., et al.
Publicado: (2023)

Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups
por: Smith, Jaclyn A., et al.
Publicado: (2022)

An observational study to determine the relationship between cough frequency and markers of inflammation in severe asthma
por: Holmes, Joshua, et al.
Publicado: (2022)

Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study
por: Morice, Alyn, et al.
Publicado: (2021)

The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial
por: Friedrich, Christian, et al.
Publicado: (2023)

Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant
por: Morice, Alyn H., et al.
Publicado: (2021)

Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses
por: Song, Woo-Jung, et al.
Publicado: (2021)

Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough
por: Ludbrook, Valerie J., et al.
Publicado: (2021)

COUGH: consolidating a mature field for the next 5 years
por: Chung, Kian Fan, et al.
Publicado: (2011)

Changing the paradigm for cough: does 'cough hypersensitivity' aid our understanding?
por: Song, Woo-Jung, et al.
Publicado: (2014)

Consensus goals and standards for specialist cough clinics: the NEUROCOUGH international Delphi study
por: Song, Woo-Jung, et al.
Publicado: (2023)

Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study
por: Dicpinigaitis, Peter V., et al.
Publicado: (2023)

Burden of chronic cough in the UK: results from the 2018 National Health and Wellness Survey
por: McGarvey, Lorcan, et al.
Publicado: (2023)

Recent progress in the management of chronic cough
por: Song, Woo-Jung, et al.
Publicado: (2020)

The Skagit County choir COVID-19 outbreak – have we got it wrong?
por: Axon, C.J., et al.
Publicado: (2023)

Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough
por: Mazzone, Stuart B., et al.
Publicado: (2020)

Combating cough
por: Morice, Alyn H
Publicado: (2016)

Diabetes: Have We Got It All Wrong?: Hyperinsulinism as the culprit: surgery provides the evidence
por: Pories, Walter J., et al.
Publicado: (2012)

Chronic cough hypersensitivity syndrome
por: Morice, Alyn H
Publicado: (2013)

XII AIST 2018 Conference: “The thousand faces of cough: clinical and therapeutic updates”
por: Zanasi, Alessandro, et al.
Publicado: (2018)

Diabetes: Have We Got It All Wrong?: Insulin hypersecretion and food additives: cause of obesity and diabetes?
por: Corkey, Barbara E.
Publicado: (2012)

Objective and Subjective Measurement of Cough in Asthma: A Systematic Review of the Literature
por: Holmes, Joshua, et al.
Publicado: (2022)

Chronic Cough in Idiopathic Pulmonary Fibrosis: The Same Difference?
por: Morice, Alyn H.
Publicado: (2022)

The Cough Reflex: The Janus of Respiratory Medicine
por: Sykes, Dominic L., et al.
Publicado: (2021)

Adverse perception of cough in patients with severe asthma: a discrete choice experiment
por: Holmes, Joshua, et al.
Publicado: (2023)

Neurokinin-1 Receptor Inhibition and Cough
por: Turner, Richard D., et al.
Publicado: (2021)

Measuring cough: what really matters?
por: Turner, Richard Douglas, et al.
Publicado: (2023)

Chronic cough associated with Crohn's disease
por: Faruqi, Shoaib, et al.
Publicado: (2010)

‘Dry’ and ‘wet’ cough: how reliable is parental reporting?
por: Donnelly, Deirdre, et al.
Publicado: (2019)

The Emerging Role of The Eosinophil and Its Measurement in Chronic Cough
por: Sadeghi, Mahboobeh H., et al.
Publicado: (2017)

Sepsis Definitions: The Search for Gold and What CMS Got Wrong
por: Kalantari, Annahieta, et al.
Publicado: (2017)

Cough Hypersensitivity Syndrome: A Few More Steps Forward
por: Song, Woo-Jung, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p33h9mfrlbq0es37ec8j5qeq1g